Loading patent…
AssigneeTianjin Institute of Pharmaceutical Research
InventorsGuilong Zhao, Changying Liu, Huihui Chen, Yuquan Li, Haizhi Zhang, Xuyuan Liu, Yuqiang Liu, Yafei Xie, Jingwei Wu, Wei Liu, Weiren Xu, Lida Tang, Meixiang Zou
Estimating the term…
The present invention provides a crystal form of urate transporter 1 inhibitor and a preparation method and use thereof. The crystal form is characterized by a stable state of appearance and a capability of further improving the purity and storage stability of the compound, etc., and suitable as a pharmaceutical raw material.
A crystal form of a compound represented by Formula I, characterized in that its powder X-ray diffraction pattern expressed by 20 degree using Cu-Kα radiation has diffraction peaks at 18.432 ± 1, 19.846 ± 1, 20.207 ± 1, 20.327 ± 1, 22.341 ± 1, 22.735 ± 1, 25.654 ± 1, 26.119 ± 1, 26.617 ± 1 and 33.159 ± 1,
Dependencies are inferred from the claim text.